Propanc Biopharma, Inc.
No SEC Form 4 filings for $PPCB in the last 30 days.
See all $PPCB insider activity →Propanc Biopharma (PPCB) reported preclinical data for its PRP treatment in advanced pancreatic cancer, which has FDA Orphan Drug Designation. The company plans to begin a Phase 1b clinical trial in Q1 2027. PRP is still in early-stage development, and further regulatory approvals are required.
Propanc Biopharma (Nasdaq: PPCB) reported preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic cancer models. PRP targets different mechanisms than Revolution Medicines' recently approved daraxonrasib, which showed median overall survival of 13.2 months in clinical trials. Propanc plans to start a Phase 1b study in early 2027.
Propanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PPCB (Propanc Biopharma, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent PPCB coverage spans financial news, technology and corporate actions.
Positive preclinical results may lift sentiment and attract speculative buying.
Positive preclinical results could boost investor sentiment and drive short-term upside.
Positive preclinical results could boost investor optimism and support a higher valuation ahead of Phase 1b filing.
Board composition and director compensation details are unlikely to change near-term fundamentals, but they can affect governance optics and committee structure.
The MOU is a clinical execution milestone that can improve perceived readiness for Phase 1b, but it is not a binding contract or trial result.
AlphAI scores every news story that mentions PPCB with an AI model for sentiment and relevance, and aggregates insider trades from Propanc Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Propanc Biopharma (PPCB) reported preclinical data for its PRP treatment in advanced pancreatic cancer, which has FDA Orphan Drug Designation. The company plans to begin a Phase 1b clinical trial in Q1 2027. PRP is still in early-stage development, and further regulatory approvals are required.
1 min readPropanc Biopharma (Nasdaq: PPCB) reported preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic cancer models. PRP targets different mechanisms than Revolution Medicines' recently approved daraxonrasib, which showed median overall survival of 13.2 months in clinical trials. Propanc plans to start a Phase 1b study in early 2027.
2 min readPropanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.
2 min readPropanc Biopharma, Inc. (PPCB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 INDEPENDENT DIRECTOR AGREEMENT THIS INDEPENDENT DIRECTOR AGREEMENT (this “ Agreement ”), is made effective as of July 8, 2026, and is by and between Propanc Biopharma, Inc., a Delaware corporation (the “ Company ”), and the undersigned (t
2 min readPropanc Biopharma (PPCB) said it signed an MOU with Avance Clinical Pty Ltd to collaborate on clinical delivery of its planned Phase 1b first-in-human trial of PRP for advanced solid tumors. The study will assess safety, tolerability, pharmacokinetics, immunogenicity, and preliminary activity. PPCB also noted a 1-for-25 reverse split on May 18, 2026.
4 min readPropanc Biopharma (Nasdaq: PPCB) said it signed an MOU with Avance Clinical Pty Ltd to support delivery of Propanc’s Phase 1b first-in-human trial of PRP in advanced solid tumors. The CRO will help with trial design and execution, aiming to generate data to move PRP toward proof-of-concept and later phases.
3 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min readPropanc Biopharma, Inc. (PPCB) shares rose about 26% after the company said it started a share repurchase program to buy a first tranche of up to $500,000 over 30 days. The stock was around $1.8150 on Nasdaq, up about 25.7% in the latest session.
2 min readPropanc Biopharma, Inc. (Nasdaq: PPCB) said it has started a share repurchase program authorizing a first tranche of up to $500,000 to buy back common stock over the next 30 days. Purchases may occur under Rule 10b5-1 and other methods, and the company may modify, suspend, or end the program at any time.
3 min readPropanc Biopharma (PPCB) said its board approved a share repurchase program authorizing buybacks of up to $5.0 million of its common stock. The company expects the program to support shareholder ownership and improve per-share economics, citing management’s capital allocation approach. In pre-market trading, PPCB was at $2.87, up 114.23% on Nasdaq.
2 min read
